Published on 20 Feb 2022 on Benzinga
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead...
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
On the regulatory front, the Food and Drug Administration approved Agios Pharmaceuticals, Inc.'s (NASDAQ: AGIO) mitapivat for treating pyruvate kinase deficiency, a rare, inherited metabolic disorder.
NYSE.GKOS price evolution
NASDAQ.HALO price evolution
NASDAQ.HCAT price evolution
NASDAQ.ABCL price evolution
NASDAQ.EDIT price evolution
NASDAQ.NEO price evolution
NASDAQ.NARI price evolution
NASDAQ.MMSI price evolution
NASDAQ.NTRA price evolution
NASDAQ.MGNX price evolution
NASDAQ.MASI price evolution
NASDAQ.PTC price evolution
NASDAQ.BMRN price evolution
NASDAQ.GH price evolution
NASDAQ.VIR price evolution
NASDAQ.PODD price evolution
NASDAQ.EXAS price evolution
NASDAQ.RETA price evolution
NASDAQ.NUVA price evolution
NASDAQ.IMGN price evolution
NASDAQ.SGMO price evolution
NYSE.NVTA price evolution
NASDAQ.PCRX price evolution
NASDAQ.IOVA price evolution
NASDAQ.PDSB price evolution
NASDAQ.AGIO price evolution
NASDAQ.CDNA price evolution
NASDAQ.CDXS price evolution
NASDAQ.OPK price evolution
NYSE.AVNS price evolution
NASDAQ.SNY price evolution
NASDAQ.ICUI price evolution
NASDAQ.LMAT price evolution
Want to become a better investor?
Start tracking your investments with Statfolio
Sign up for free